Evaluating Neurotherapeutic Potential of Myricetin by In-Vivo research models

Background: Oxidative stress, neuroinflammation, and poor neurotrophic signaling are associated with neurological diseases. Myricetin is a bioflavonoid present in berries, vegetables, and medicinal herbs, with strong anti-inflammatory, antioxidant, and neurotrophic properties in animal studies. The objective of the present in-vivo research was to assess the neuroprotective potential of myricetin on nerve growth factor (NGF) expression and neuroinflammation in chemically induced neural injury. Materials and Methods: Thirty healthy male adult Wistar rats (180-220g, 8 weeks old) were randomly divided into five groups (n=6 per group). Group I was used as a control, with no intervention. Groups II to V were exposed to a standard propionic acid (PPA) to induce neuroinflammation. Groups III-V were induced and subsequently administered with oral myricetin of 50 mg/kg, 100 mg/kg, and 200 mg/kg for 28 days. Serum levels of NGF were measured with Enzyme-linked Immunosorbent assay (ELISA). One-way ANOVA was performed for statistical analysis using SPSS. Results: PPA decreased NGF to 4.3 ± 0.5 pg/ml (p< 0.001). Myricetin restored NGF to 9.3, 7.6, and 9.8 pg/mL via 50, 100, and 200 mg/kg doses, respectively. At 200 mg/kg, C-reactive protein (CRP), tumor necrosis factor (TNF), and malondialdehyde (MDA) were decreased to 1.7 ± 0.2 mg/L, 26 ± 3 pg/mL, and 2.9 ± 0.3 nmol/mg, compared to 4.9 ± 0.4, 58 ± 4, and 6.7 ± 0.4. (p < 0.001). Conclusion: Myricetin exhibits promising neurotherapeutic potential, evidenced by its ability to upregulate NGF and mitigate neuroinflammatory damage, making it a potential therapeutic option for the treatment of neurological disorders.